Aarti Drugs Ltd reported a healthy set of numbers for the March quarter of FY25, with net profit climbing 32.7% year-on-year to ₹62.9 crore, up from ₹47.4 crore in the same quarter last year.
The performance was supported by a 9.2% increase in revenue, which stood at ₹677 crore compared to ₹620 crore a year ago, indicating improved demand conditions and higher volumes.
Operating performance also saw an uptick, with EBITDA rising 8.9% YoY to ₹93.4 crore from ₹85.8 crore. However, margins remained steady at 13.8%, broadly unchanged from the year-ago period, suggesting cost pressures continued to offset gains from revenue growth.
Also Read: Q4 Results Live Updates: Bank of Baroda drops 11% after NII miss
Ahead of earnings announcement, shares of Aarti Drugs ended 1.87% lower at ₹349 on the BSE.
Also Read: Alembic Pharma Q4 Results: US business grows 20%, strong growth in India branded division
